This multi-jurisdictional guide covers common issues in pharmaceutical advertising laws and regulations.
Topics covered include advertisements to healthcare professionals, gifts and financial incentives, hospitality and related payments, and transparency and disclosure.
The U.S. Supreme Court’s decision overturning Chevron deference. This articles discusses the ruling, which calls for courts to reassume their role as interpreters of the law.
This article provides an overview of the False Claims Act (FCA).
In this article you will learn about, the types of FCA cases in health care, damages and penalties under the FCA, and cooperation considerations for companies and individuals under government scrutiny.
Foley & Lardner’s Top Trends for 2024 publication unpacks key developments in an uncertain regulatory landscape.
On April 23, 2024, the U.S. Federal Trade Commission finalized a rule, by a vote of 3-2, abolishing the vast majority of employee covenants not to compete across the United States.
While certain health care providers will be exempted from the rule, many will not. As such, and if the rule survives legal challenge, health care industry participants should carefully consider how the rule will impact their recruitment and retention strategies going forward.